Many breast cancers have estrogen receptors (ER), and the growth of these tumors can be stimulated by estrogen. Fulvestrant down regulates the ER protein in human breast cancer cells. Fulvestrant is an ideal candidate for transdermal drug delivery because of it has a low oral bioavailability and suitable partition coefficient value (1.99) for a drug to be eligible for transdermal delivery systems, i.e. value is in the range of 1-3 and this is an important prerequisite for any product to be administered through transdermal drug delivery system, for its therapeutic applications. In this study, it has been demonstrated that fulvestrant can be administered through transdermal application with predetermined targeted release. Formulations have been characterized by FTIR to evaluate any interaction of the drug with the vehicles or inactive ingredients used in the preparation of patches. Transdermal patches were prepared, using reservoir concept and were subjected to in-vitro skin permeability studies. The data obtained from invitro skin permeability studies is fitted with kinetic models to determine drug release mechanism, and it was found that the drug release pattern follows zero order kinetics. Also it has been demonstrated that targeted concentration has been achieved in the in one of the formulations tested. These preliminary studies can lead to further studies to evaluate the formulations to achieve therapeutic levels by conducting in in-vivo also. Fulvestrant transdermal patch provides ease of application over the current marketed formulation which is given by intramuscular route which is a painful for the patients due to its composition.